JP6055417B2 - 放射性トレーサー組成物 - Google Patents

放射性トレーサー組成物 Download PDF

Info

Publication number
JP6055417B2
JP6055417B2 JP2013542563A JP2013542563A JP6055417B2 JP 6055417 B2 JP6055417 B2 JP 6055417B2 JP 2013542563 A JP2013542563 A JP 2013542563A JP 2013542563 A JP2013542563 A JP 2013542563A JP 6055417 B2 JP6055417 B2 JP 6055417B2
Authority
JP
Japan
Prior art keywords
composition
formula
btm
group
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013542563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014500268A (ja
JP2014500268A5 (OSRAM
Inventor
エンジェル，トルグリム
グリッグ，ジュリアン
マンジラス，ディミトリオス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of JP2014500268A publication Critical patent/JP2014500268A/ja
Publication of JP2014500268A5 publication Critical patent/JP2014500268A5/ja
Application granted granted Critical
Publication of JP6055417B2 publication Critical patent/JP6055417B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2013542563A 2010-12-09 2011-12-09 放射性トレーサー組成物 Active JP6055417B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42139010P 2010-12-09 2010-12-09
US61/421,390 2010-12-09
PCT/EP2011/072352 WO2012076697A1 (en) 2010-12-09 2011-12-09 Radiotracer compositions

Publications (3)

Publication Number Publication Date
JP2014500268A JP2014500268A (ja) 2014-01-09
JP2014500268A5 JP2014500268A5 (OSRAM) 2015-01-29
JP6055417B2 true JP6055417B2 (ja) 2016-12-27

Family

ID=45346469

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013542563A Active JP6055417B2 (ja) 2010-12-09 2011-12-09 放射性トレーサー組成物

Country Status (7)

Country Link
US (2) US9180213B2 (OSRAM)
EP (1) EP2648767B1 (OSRAM)
JP (1) JP6055417B2 (OSRAM)
KR (1) KR20130124522A (OSRAM)
CN (2) CN103338791A (OSRAM)
CA (1) CA2820387A1 (OSRAM)
WO (1) WO2012076697A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202420D0 (en) * 2012-02-13 2012-03-28 Ge Healthcare Ltd Radiotracer compositions
WO2013176522A1 (ko) * 2012-05-24 2013-11-28 서강대학교산학협력단 카트리지를 이용한 방사성의약품 제조방법
GB201221266D0 (en) * 2012-11-27 2013-01-09 Ge Healthcare Ltd Aldehyde compositions
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
EP3226884B1 (en) * 2014-12-04 2021-02-17 GE Healthcare Limited Method of removing acetaldehyde from radioactive pharmaceuticals

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
US7659400B2 (en) * 2003-07-31 2010-02-09 Washington University Radiolabelled benzamide analogues, their synthesis and use in diagnostic imaging
GB0420344D0 (en) 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
WO2007027385A2 (en) * 2005-08-31 2007-03-08 Immunomedics, Inc. F-18 peptides for pre targeted positron emission tomography imaging
EP2567711A3 (en) * 2007-02-07 2013-05-01 Purdue Research Foundation Positron emission tomography imaging method
WO2009002914A2 (en) 2007-06-25 2008-12-31 Interdigital Technology Corporation Method and apparatus for supporting inter-frequency and inter-radio access technology handover
US8124725B2 (en) 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders
WO2010000409A2 (en) 2008-07-03 2010-01-07 Bayer Schering Pharma Aktiengesellschaft Compounds and processes for production of radiopharmaceuticals
GB0905438D0 (en) * 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
EP2322500A1 (en) * 2009-11-11 2011-05-18 Bayer Schering Pharma Aktiengesellschaft Fluoro-labeled homo-glutamate derivatives and precursors thereof
BR112012011786A2 (pt) * 2009-11-17 2019-09-24 Bayer Pharma AG "método para a produção de derivados de ácido glutâmico marcados por f-18"

Also Published As

Publication number Publication date
CN103338791A (zh) 2013-10-02
EP2648767B1 (en) 2023-03-15
KR20130124522A (ko) 2013-11-14
US9180213B2 (en) 2015-11-10
US20130259804A1 (en) 2013-10-03
JP2014500268A (ja) 2014-01-09
CA2820387A1 (en) 2012-06-14
WO2012076697A1 (en) 2012-06-14
US9987382B2 (en) 2018-06-05
EP2648767A1 (en) 2013-10-16
US20160022847A1 (en) 2016-01-28
CN107753962A (zh) 2018-03-06

Similar Documents

Publication Publication Date Title
US9533059B2 (en) Peptide radiotracer compositions
JP6055417B2 (ja) 放射性トレーサー組成物
JP5860808B2 (ja) 放射性ヨウ素化方法
US20210330824A1 (en) Purification method and compositions
JP2014505021A (ja) アポトーシス用ｐｅｔイメージング剤
CN105848687A (zh) 放射性示踪剂组合物和方法
US20150139902A1 (en) Purification of [18f] - fluciclatide
US20130209358A1 (en) Radiotracer compositions
JP6231882B2 (ja) 放射性コンジュゲーション方法
JP6650873B2 (ja) 放射性標識方法
JP6280507B2 (ja) キレート剤
JP2016506375A (ja) 放射性フッ素化のための１８ｆ標識アルデヒド組成物
JP2015504875A (ja) 放射性フッ素化方法
CN105339013A (zh) 金属络合物及其氟化

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160816

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161202

R150 Certificate of patent or registration of utility model

Ref document number: 6055417

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250